Researchers from Mass General Brigham and the University of Cyprus have developed a mathematical model to better understand how the tumor microenvironment affects the delivery and effectiveness of a new type of cancer therapy called an immunomodulatory antibody-drug conjugate (IM-ADC). The work is published in the Journal for ImmunoTherapy of Cancer.